NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Clinical trial NCT03789110 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03789110
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-08
- Primary completion
- 2021-09-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.